Takeda buys Inviragen for $35mm plus up to $215mm in earn-outs
Takeda Pharmaceutical Co. Ltd. is continuing to grow its vaccines business, this time through the acquisition of Inviragen Inc., a privately owned biotech with projects in preclinical through Phase II trials for various infectious diseases. Takeda paid $35mm in cash up front, and could hand over up to an additional $215mm in development and commercialization earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.